-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We keep our target price at $14.00, based on a P/E of 3.8x our 2027 EPS estimate. We lower our 2026 EPS estimate to $3.40 from $3.62 and maintain our 2027 EPS estimate at $3.71. Organon reported mixed Q1 2026 results, with revenues declining 4% Y/Y to $1,460M (-9% on a constant currency basis), reflecting headwinds across its Women's Health franchise, with sales down 16% Y/Y, particularly for Nexplanon. Yet, the company's biosimilar portfolio delivered robust growth, with revenues advancing 23% Y/Y, led by Hadlima's strong U.S. performance. Looking ahead, the successful closing of the pending Sun Pharmaceutical acquisition will be the key focus. On April 26, the company entered into a definitive merger agreement with Sun Pharmaceutical, which valued Organon at $11.75B. Joseph Morrissey, previously serving as Interim CEO, was appointed to the role on a permanent basis, which eliminates leadership uncertainty during this critical period, in our view.